BioPharma Clinical Trials

Clinical Trial Approval For mRNA Covid-19 Vaccine For Omicron Variant In The Philippines

R520A is an mRNA COVID-19 vaccine specifically targeting the Omicron variant developed by Wuhan Recogen Biotechnology Co., Ltd., a subsidiary of the Compan...

 June 28, 2022 | News

Antengene Announces Clinical Trial Collaboration with BeiGene

Selinexor is an oral small molecule XPO1 inhibitor; tislelizumab is an anti-PD-1 checkpoint inhibitor Antengene Corporation Limited ("...

 June 27, 2022 | News

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients Priority Review requested; if accepted, anticipate an 8-mont...

 June 23, 2022 | News

JNCCN: Mismatch in Breast Cancer Trial Results and Real-World Outcomes Based on Treatment Discontinuation

New research in the June 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network raises issues with clinical tri...

 June 22, 2022 | News

WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotech...

 June 16, 2022 | News

Evonik launches new peptide to boost productivity of cell-culture-based biopharmaceuticals

Evonik now offers a highly pure cystine peptide to address challenges in the formulation of cell culture media and processes used in the development and pr...

 June 07, 2022 | News

CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer

CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative im...

 June 07, 2022 | News

4P-Pharma and Delta 4 Join Forces to Find and Develop Treatments for a Rare Autoimmune Chronic Liver Disease

Contributing to this collaboration, Delta 4 will apply its proprietary computational and iterative big data analytics platform to identify novel therapeuti...

 June 03, 2022 | News

United BioPharma Receives TFDA Approval for Phase 2 IND for UB-221 to Treat Chronic Spontaneous Urticaria

This Phase 2 clinical trial (double-blind, placebo-controlled) aims to evaluate the efficacy of UB-221 as a long-acting add-on therapy for treatment of chr...

 May 31, 2022 | News

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

 Encouraging efficacy signals were observed in a non-small cell lung cancer (NSCLC) patient cohort -  Results indicate CD73 expression corr...

 May 27, 2022 | News

Antengene Announces Addition of Multiple XPOVIO® Treatment Regimens for Myeloma and Lymphoma in 2022 CSCO Guidelines

The 2022 CSCO Guidelines incorporate a total of four selinexor combination therapy regimens for relapsed myeloma. In addition, the guidelines also recommen...

 May 13, 2022 | News

Clinical Trial Approval For ReCOV In The PRC And The Overseas Clinical Trial Progress Of ReCOV

As disclosed in the prospectus of the Company dated March 21, 2022, the Group had initiated subject enrollment for the phase II/III clinical trial for...

 May 06, 2022 | News

Inmagene Receives FDA's IND Clearance for OX40 Antagonist

IMG-007 is highly potent at blocking the binding of OX40 to OX40L, thereby reducing OX40L-dependent downstream signaling and cytokine release by T cells. I...

 May 02, 2022 | News

Lessons Learned from COVID-19 Vaccine Trials

    IQVIA Institute releases report on Lessons Learned from COVID-19 Vaccine Trials Solutions for you to dri...

 April 28, 2022 | News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in